Plozasiran, a first-in-class RNA interference therapeutic, reduced triglycerides by 80% and lowered the risk of acute pancreatitis by 83% in patients with familial chylomicronemia syndrome, earning FDA...
Crinecerfont, a first-in-class therapy, improved androgen control and reduced reliance on high-dose glucocorticoids for patients with congenital adrenal hyperplasia.
The new treatment is the first FDA-approved drug to address the overproduction of cortisol in Cushing disease by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis.
The US Food and Drug Administration has granted approval to a treatment for thyroid eye disease. It is the first-ever drug to be approved for this indication.
The US Food and Drug Administration has approved the first and only fast-acting mealtime insulin injection that does not have a pre-dosing recommendation for use in children with diabetes.
